Data from ARTISTRY trials demonstrated that switching to a single-tablet regimen of bictegravir and lenacapavir is noninferior to continuing current antiretroviral therapy.
Topline data from the MagnetisMM-5 study demonstrate the superiority of elranatamab monotherapy over daratumumab plus pomalidomide and dexamethasone in double-class exposed multiple myeloma patients.
MPR spoke with Dr Daniela Carvalho, an investigator in the CHORD trial, the results form which formed the basis for the approval of Otarmeni.
HealthDay News — For adults with prediabetes, a reduction in the risk for diabetes is seen after supplementation with 4000 IU/day of vitamin D 3 among those carrying the AC and CC alleles of the Apal ...
Rectal cancer is occurring earlier and killing younger adults faster, according to a study presented at Digestive Disease Week 2026, held from May 2 to 5 in Chi ...
Difference in total body weight loss between the treatment and control groups widened with time postintervention.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results